Human TGFBR2/SMAD234-Luc Reporter Cell Line - HEK293

The Human TGFBR2/SMAD234-Luc Reporter Cell Line - HEK293 is a highly engineered in vitro model built upon the foundational Human Embryonic Kidney 293 (HEK293) cell line. HEK293 cells are renowned in molecular biology for their robust adherent growth, classic epithelial morphology, and amenability to stable genetic modification. This specific reporter line is precisely engineered to co-express the human Transforming Growth Factor Beta Receptor 2 (TGFBR2)—a critical transmembrane serine/threonine kinase receptor—alongside a stably integrated firefly luciferase (Luc) reporter gene. This reporter gene is under the transcriptional control of a minimal promoter fused to multiple SMAD-binding elements (SBE). Biologically, when a TGF-β ligand binds to the overexpressed TGFBR2, it triggers a phosphorylation cascade involving downstream intracellular effectors, specifically the receptor-regulated SMAD2 and SMAD3 proteins. Once phosphorylated, they form a complex with the common-mediator SMAD4 and translocate to the nucleus. This active SMAD2/3/4 complex binds directly to the SBE promoter sequence, initiating the transcription of the luciferase enzyme. As a result, the cells generate a robust, highly quantifiable bioluminescent signal that directly correlates with the activation status of the TGF-β signaling axis.

The dynamic and highly responsive nature of this reporter cell line makes it an indispensable tool for both fundamental signal transduction research and extensive drug discovery pipelines. In laboratory environments, the continuous bioluminescent output serves as a highly sensitive, real-time metric for quantifying TGF-β pathway activation. This establishes an ideal platform for the high-throughput screening (HTS) and characterization of novel pharmacological agents, including small-molecule kinase inhibitors targeting TGF-β receptors, recombinant neutralizing antibodies, and pathway agonists. Because the TGF-β/SMAD signaling cascade is fundamentally implicated in critical pathological conditions—most notably severe tissue fibrosis, immune evasion in the tumor microenvironment, and cancer metastasis driven by the epithelial-mesenchymal transition (EMT)—this cell line is exceptionally valuable for oncological and fibrotic disease research.